











## **Prior Authorization Request Administrative Information**

Member Information					
Last name	First name		МІ		
Member ID	Date of birth				
	X" or Intersex				
Current gender  Female  Male  Transge	ender male 🔲 Tra	nsgender female  Othe	-		
Place of residence Home Nursing facility	Other				
Race/ethnicity Preferred spoken la	anguage	Preferred written lang	uage		
MassHealth does not exclude people or treat them differently because of race, color, national origin, age, disability, religion, creed, sexual orientation, or sex (including gender identity and gender stereotyping).					
Plan Contact Information					
Please indicate the member's MassHealth Plan according to the Plan's contact information belo		his completed and signed	form		
MassHealth Fee-For-Service (FFS) Plan, Primary Care Clinician (PCC) Plan, Primary Care Accountable Care Organization (PCACO) Plan, Children's Medical Security Plan, and Health Safety Net Plan					
☐ MassHealth Drug Utilization Review Prog	gram				
Pharmacy: Fax: (877) 208-7428 - Tel: (800	Pharmacy: Fax: (877) 208-7428 - Tel: (800) 745-7318				
MassHealth Managed Care Organization	n (MCO) and Acco	untable Care Partnershi	p Plans (ACPP)		
☐ Fallon Health					
Online Prior Authorization: go.covermymeds.com/OptumRx					
Online Prior Authorization: providerportal.surescripts.net/ProviderPortal/optum					
Pharmacy: Fax: (844) 403-1029 - Tel: (844) 720-0033					
☐ Health New England					
Online Prior Authorization: go.covermymeds.com/OptumRx					
Pharmacy: Fax: (800) 550-9246 - Tel: (800) 918-7545					
Online Prior Authorization (Non-Specialty Drugs): go.covermymeds.com/OptumRx					
Online Prior Authorization (Specialty/Medical Drugs): provider.massgeneralbrighamhealthplan.org					
Pharmacy: Fax: (844) 403-1029 - Tel: (800) 711-4555					
☐ Tufts Health Plan					
Online Prior Authorization: point32health.pr	romptpa.com				
Pharmacy: Fax: (617) 673-0939 - Tel: (888	3) 257-1985				
☐ WellSense Health Plan					
Online Prior Authorization: wellsense.org/p	roviders/ma/pharma	acy/prior-authorizations			
Pharmacy: Fax: (833) 951-1680 - Tel: (877) 417-1822					

## Pediculicides and Scabicides Prior Authorization Request

MassHealth reviews requests for prior authorization (PA) on the basis of medical necessity only. If MassHealth approves the request, payment is still subject to all general conditions of MassHealth, including current member eligibility, other insurance, and program restrictions. MassHealth will notify the requesting provider and member of its decision. Keep a copy of this form for your records. If faxing this form, please use black ink.

Additional information about these agents, including PA requirements and preferred products, can be found within the MassHealth Drug List at **www.mass.gov/druglist**.

Medication informati Medication requested					
crotamiton lotion	☐ lindane s	shampoo	☐ ma	athion	spinosad
Dose, frequency, and	duration of med	lication rec	quested		
Indication or ICD-10	code, if applicabl	le			
Crab lice	Head lice	☐ Scabie	es [	Other (plea	ase indicate)
Section I. Please complete for lindane shampoo requests.  1. Has the member had a trial with a permethrin or piperonyl butoxide/pyrethrins product?  Yes. Please list the drug name, dates/duration of trials, and outcomes below.*					
			/ing? □		of use Inadequate response Other contraindication, or other.
☐ No. Please des	cribe clinical ratio	nale for not	using pe	rmethrin and	piperonyl butoxide/pyrethrins for this
2. Has the member h	ad a trial with mal		on of tria	s, and outcor	mes below.*
Dates/duration of use  Did the member experience any of the following?   Adverse reaction   Inadequate response   Other Briefly describe details of adverse reaction, inadequate response, contraindication, or other.					
□ No. Please des	cribe clinical ratio	nale for not	using m	alathion for th	is member.
* Please attach a letter documenting additional trials as necessary.					
Section II. Please complete for crotamiton lotion requests.  1. Has the member had a trial with permethrin 5%?  Yes. Please list the drug name, dates/duration of trials, and outcomes below.*  Dates/duration of use  Did the member experience any of the following? Adverse reaction Inadequate response Other Briefly describe details of adverse reaction, inadequate response, contraindication, or other.					

PA-42 (Rev. 04/24) over

2. Has the member had a trial with oral ivermectin?    Yes. Please list the drug name, dates/duration of trials, and outcomes below.*   Dates/duration of use     Did the member experience any of the following?   Adverse reaction   Inadequate response   Other Briefly describe details of adverse reaction, inadequate response, contraindication, or other.   No. Please describe clinical rationale for not using oral ivermectin for this member.   No. Please describe clinical rationale for not using oral ivermectin for this member.   No. Please describe clinical rationale for not using oral ivermectin for this member.   Other Briefly describe details of adverse reaction, inadequate response   Other Briefly describe details of adverse reaction, inadequate response, or other.   No. Please describe clinical rationale for not using crotamiton cream for this member.   No. Please attach a letter documenting additional trials as necessary.   Section III. Please complete for malathion, and spinosad requests.   Has the member had a trial with permethrin or piperonyl butoxide/pyrethrins?   Yes. Please list the drug name, dates/duration of trials, and outcomes below.*   Drug name			No. Please describe clinical rationale for not using permethrin 5% for this member.
Dates/duration of use  Did the member experience any of the following?  Adverse reaction  Inadequate response  Other Briefly describe details of adverse reaction, inadequate response, contraindication, or other.  No. Please describe clinical rationale for not using oral ivermectin for this member.  3. Has the member had a trial with crotamiton cream?   Yes. Please list dates/duration of trials, and outcomes below.  Dates/duration of use  Did the member experience any of the following?  Adverse reaction  Inadequate response  Other Briefly describe details of adverse reaction, inadequate response, or other.  No. Please describe clinical rationale for not using crotamiton cream for this member.  **Please attach a letter documenting additional trials as necessary.  Section III. Please complete for malathion, and spinosad requests. Has the member had a trial with permethrin or piperonyl butoxide/pyrethrins?  Yes. Please list the drug name, dates/duration of trials, and outcomes below.*  Drug name Dates/duration of use Did the member experience any of the following?  Adverse reaction  Inadequate response Other Briefly describe details of adverse reaction, inadequate response, contraindication, or other.  No. Please describe clinical rationale for not using permethrin and piperonyl butoxide/pyrethrins for this member.  **Please attach a letter documenting additional trials as necessary.  Section IV. Please complete and provide documentation for exceptions to Step Therapy.  1. Is the alternative drug required under the step therapy protocol contraindicated, or will likely cause an adverse reaction in, or physical or mental harm to the member?  Yes  No  If yes, briefly describe details of contraindication, adverse reaction, or harm.	2.		
Did the member experience any of the following?  Adverse reaction  Inadequate response  Other Briefly describe details of adverse reaction, inadequate response, contraindication, or other.    No. Please describe clinical rationale for not using oral ivermectin for this member.   No. Please describe clinical rationale for not using oral ivermectin for this member.   Alas the member had a trial with crotamiton cream?			
No. Please describe clinical rationale for not using oral ivermectin for this member.  3. Has the member had a trial with crotamiton cream?  Yes. Please list dates/duration of trials, and outcomes below. *  Dates/duration of use  Did the member experience any of the following? ☐ Adverse reaction ☐ Inadequate response ☐ Other Briefly describe details of adverse reaction, inadequate response, or other.  No. Please describe clinical rationale for not using crotamiton cream for this member.  *Please attach a letter documenting additional trials as necessary.  Section III. Please complete for malathion, and spinosad requests.  Has the member had a trial with permethrin or piperonyl butoxide/pyrethrins?  Yes. Please list the drug name, dates/duration of trials, and outcomes below.*  Drug name ☐ Dates/duration of use ☐ Did the member experience any of the following? ☐ Adverse reaction ☐ Inadequate response ☐ Other Briefly describe details of adverse reaction, inadequate response, contraindication, or other.  No. Please describe clinical rationale for not using permethrin and piperonyl butoxide/pyrethrins for this member.  *Please attach a letter documenting additional trials as necessary.  Section IV. Please complete and provide documentation for exceptions to Step Therapy.  1. Is the alternative drug required under the step therapy protocol contraindicated, or will likely cause an adverse reaction in, or physical or mental harm to the member? ☐ Yes ☐ No  If yes, briefly describe details of contraindication, adverse reaction, or harm.  □ 1. Is the alternative drug required under the step therapy protocol expected to be ineffective based on the known clinical characteristics of the member and the known characteristics of the alternative drug regimen?  Yes ☐ No			Did the member experience any of the following?   Adverse reaction   Inadequate response   Other
3. Has the member had a trial with crotamiton cream?    Yes. Please list dates/duration of trials, and outcomes below.*   Dates/duration of use			Briefly describe details of adverse reaction, inadequate response, contraindication, or other.
Yes. Please list dates/duration of trials, and outcomes below. *   Dates/duration of use     Did the member experience any of the following?   Adverse reaction   Inadequate response   Other Briefly describe details of adverse reaction, inadequate response, or other.     No. Please describe clinical rationale for not using crotamiton cream for this member.     * Please attach a letter documenting additional trials as necessary.    Section III. Please complete for malathion, and spinosad requests.     Has the member had a trial with permethrin or piperonyl butoxide/pyrethrins?     Yes. Please list the drug name, dates/duration of trials, and outcomes below.*     Drug name   Dates/duration of use     Did the member experience any of the following?   Adverse reaction   Inadequate response   Other Briefly describe details of adverse reaction, inadequate response, contraindication, or other.     No. Please describe clinical rationale for not using permethrin and piperonyl butoxide/pyrethrins for this member.     * Please attach a letter documenting additional trials as necessary.    Section IV. Please complete and provide documentation for exceptions to Step Therapy.			No. Please describe clinical rationale for not using oral ivermectin for this member.
Did the member experience any of the following?  Adverse reaction  Inadequate response  Other Briefly describe details of adverse reaction, inadequate response, or other.    No. Please describe clinical rationale for not using crotamiton cream for this member.	3.		
Briefly describe details of adverse reaction, inadequate response, or other.  No. Please describe clinical rationale for not using crotamiton cream for this member.  * Please attach a letter documenting additional trials as necessary.  Section III. Please complete for malathion, and spinosad requests.  Has the member had a trial with permethrin or piperonyl butoxide/pyrethrins?  Yes. Please list the drug name, dates/duration of trials, and outcomes below.*  Drug name  Dates/duration of use  Did the member experience any of the following? Adverse reaction Inadequate response Other Briefly describe details of adverse reaction, inadequate response, contraindication, or other.  No. Please describe clinical rationale for not using permethrin and piperonyl butoxide/pyrethrins for this member.  * Please attach a letter documenting additional trials as necessary.  Section IV. Please complete and provide documentation for exceptions to Step Therapy.  1. Is the alternative drug required under the step therapy protocol contraindicated, or will likely cause an adverse reaction in, or physical or mental harm to the member? Yes No  If yes, briefly describe details of contraindication, adverse reaction, or harm.			Dates/duration of use
* Please attach a letter documenting additional trials as necessary.  Section III. Please complete for malathion, and spinosad requests.  Has the member had a trial with permethrin or piperonyl butoxide/pyrethrins?    Yes. Please list the drug name, dates/duration of trials, and outcomes below.*    Drug name			
* Please attach a letter documenting additional trials as necessary.  Section III. Please complete for malathion, and spinosad requests.  Has the member had a trial with permethrin or piperonyl butoxide/pyrethrins?    Yes. Please list the drug name, dates/duration of trials, and outcomes below.*    Drug name			No. Please describe clinical rationale for not using crotamiton cream for this member.
Section III. Please complete for malathion, and spinosad requests.  Has the member had a trial with permethrin or piperonyl butoxide/pyrethrins?  Yes. Please list the drug name, dates/duration of trials, and outcomes below.*  Drug name  Dates/duration of use  Did the member experience any of the following? Adverse reaction Inadequate response Other Briefly describe details of adverse reaction, inadequate response, contraindication, or other.  No. Please describe clinical rationale for not using permethrin and piperonyl butoxide/pyrethrins for this member.  * Please attach a letter documenting additional trials as necessary.  Section IV. Please complete and provide documentation for exceptions to Step Therapy.  1. Is the alternative drug required under the step therapy protocol contraindicated, or will likely cause an adverse reaction in, or physical or mental harm to the member? Yes No  If yes, briefly describe details of contraindication, adverse reaction, or harm.  2. Is the alternative drug required under the step therapy protocol expected to be ineffective based on the known clinical characteristics of the member and the known characteristics of the alternative drug regimen?  Yes No			
Has the member had a trial with permethrin or piperonyl butoxide/pyrethrins?  Yes. Please list the drug name, dates/duration of trials, and outcomes below.*  Drug name  Dates/duration of use  Did the member experience any of the following? Adverse reaction Inadequate response Other Briefly describe details of adverse reaction, inadequate response, contraindication, or other.  No. Please describe clinical rationale for not using permethrin and piperonyl butoxide/pyrethrins for this member.  * Please attach a letter documenting additional trials as necessary.  Section IV. Please complete and provide documentation for exceptions to Step Therapy.  1. Is the alternative drug required under the step therapy protocol contraindicated, or will likely cause an adverse reaction in, or physical or mental harm to the member? Yes No  If yes, briefly describe details of contraindication, adverse reaction, or harm.  2. Is the alternative drug required under the step therapy protocol expected to be ineffective based on the known clinical characteristics of the member and the known characteristics of the alternative drug regimen?  Yes No	* F	Pleas	se attach a letter documenting additional trials as necessary.
Did the member experience any of the following? ☐ Adverse reaction ☐ Inadequate response ☐ Other Briefly describe details of adverse reaction, inadequate response, contraindication, or other.  ☐ No. Please describe clinical rationale for not using permethrin and piperonyl butoxide/pyrethrins for this member.  * Please attach a letter documenting additional trials as necessary.  Section IV. Please complete and provide documentation for exceptions to Step Therapy.  1. Is the alternative drug required under the step therapy protocol contraindicated, or will likely cause an adverse reaction in, or physical or mental harm to the member? ☐ Yes ☐ No  If yes, briefly describe details of contraindication, adverse reaction, or harm.  ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐		s the Yes	e member had a trial with permethrin or piperonyl butoxide/pyrethrins?  s. Please list the drug name, dates/duration of trials, and outcomes below.*
* Please attach a letter documenting additional trials as necessary.  Section IV. Please complete and provide documentation for exceptions to Step Therapy.  1. Is the alternative drug required under the step therapy protocol contraindicated, or will likely cause an adverse reaction in, or physical or mental harm to the member?     Yes   No		Did	I the member experience any of the following?  Adverse reaction  Inadequate response  Other
Section IV. Please complete and provide documentation for exceptions to Step Therapy.  1. Is the alternative drug required under the step therapy protocol contraindicated, or will likely cause an adverse reaction in, or physical or mental harm to the member?     Yes		No.	Please describe clinical rationale for not using permethrin and piperonyl butoxide/pyrethrins for this member.
<ol> <li>Is the alternative drug required under the step therapy protocol contraindicated, or will likely cause an adverse reaction in, or physical or mental harm to the member?  Yes  No         If yes, briefly describe details of contraindication, adverse reaction, or harm.         </li> <li>Is the alternative drug required under the step therapy protocol expected to be ineffective based on the known clinical characteristics of the member and the known characteristics of the alternative drug regimen?         Yes  No     </li> </ol>	* F	leas	se attach a letter documenting additional trials as necessary.
clinical characteristics of the member and the known characteristics of the alternative drug regimen?  ☐ Yes ☐ No	1. I	s the	e alternative drug required under the step therapy protocol contraindicated, or will likely cause an adverse tion in, or physical or mental harm to the member? $\square$ Yes $\square$ No
clinical characteristics of the member and the known characteristics of the alternative drug regimen?  ☐ Yes ☐ No			
If yes, briefly describe details of known clinical characteristics of member and alternative drug regimen.		clinic	cal characteristics of the member and the known characteristics of the alternative drug regimen?
			yes, briefly describe details of known clinical characteristics of member and alternative drug regimen.

3.	Has the member previously tried the alternative drug required under the step therapy protocol, or another alternative drug in the same pharmacologic class or with the same mechanism of action, and such alternative drug was discontinued due to lack of efficacy or effectiveness, diminished effect, or an adverse event?  Yes No If yes, please provide details for the previous trial.			
	Drug name Dates/duration of use			
	Did the member experience any of the following?  Adverse reaction  Inadequate response			
	Briefly describe details of adverse reaction or inadequate response.			
4.	Is the member stable on the requested prescription drug prescribed by the health care provider, and switching drugs will likely cause an adverse reaction in or physical or mental harm to the member?			
	☐ Yes. Please provide details. ☐ No			

Please continue to next page and complete Prescriber and Provider Information section.

## **Prior Authorization Request Prescriber and Provider Information**

Prescriber Information		
Last name*	First name*	MI
NPI*	Individual MH Provide	er ID
DEA No.	Office Contact Name	
Address	City	State Zip
Email address		
Telephone No.*	Fax No.*	
* Required		
Please also complete for professionally	administered medication	ns, if applicable.
Start date	End date	
Servicing prescriber/facility name		☐ Same as prescribing provider
Servicing provider/facility address		
Servicing provider NPI/tax ID No.		
Name of billing provider		
Billing provider NPI No.		
Is this a request for recertification?  Yes	] No	
CPT code No. of visits	J code	No. of units
Prescribing provider's attestation, signal certify under the pains and penalties of perjoinformation section of this form. Any attached I certify that the medical necessity information complete, to the best of my knowledge. I under prosecution for any falsification, omission, or	ury that I am the prescribing I statement on my letterhead (per 130 CMR 450.204) on erstand that I may be subject concealment of any material	has been reviewed and signed by me. this form is true, accurate, and to civil penalties or criminal I fact contained herein.
Prescribing provider's signature		_
Printed name of prescribing provider  (The form can either be signed by hand and		

(The form can either be signed by hand and then scanned, or it can be signed electronically using DocuSign or Adobe Sign. For electronic signatures, the signer can upload a picture of their wet signature. The typed text of a signature is not an acceptable form of an electronic signature.)